| 2022-THOM-69904 | |
| Researchers at Purdue University have developed a method for continuous flow microfluidic synthesis of benzodiazepines such as Lorazepam. Lorazepam is a commonly used sedative and is classified as an 'Essential Medicine' by the World Health Organization. However, the drug is subject to periodic shortages as the U.S. lacks domestic manufacturing capability. What's more, the drug is produced batchwise, a process that suffers from process irreproducibility issues, inability to scale readily and large time consumption. The Purdue researchers established a method--the reagents, catalysts, solvents, process conditions (temperature, pressure, flow rate, residence time), and equipment--for high throughput, continuous synthesis of Lorazepam at high yield and purity in a single reactor. The researchers propose a five-step process with a total residence time of 72.5 minutes. Related Publication: Development of a Continuous Flow Synthesis of Lorazepam. Shruti A. Biyani, Corryn Lytle, Seok-Hee Hyun, Michael A. McGuire, Ranya Pendyala, and David H. Thompson. Organic Process Research & Development 2022 26 (9), 2715-2727. DOI: 10.1021/acs.oprd.2c00184 Technology Validation: A step-by-step comparison of batch and continuous flow synthesis of Lorazepam was done, and it was found that the five-step continuous flow synthesis had a significantly reduced total synthesis time, improved yield of product at each step and minimized impurities, and it avoided purification methods such as column chromatography and used milder, safer, and sustainable reagents and solvents in each step. Under evaluation with ultra-pressure liquid chromatography (UPLC), the Lorazepam synthesized by the researchers' continuous flow process was shown to be over 99% pure. Advantages: - Continuous production - Accelerated scale-up process - > 99% purity - High yield synthesis - Use of non-toxic, sustainable reagents Applications: - Lorazepam synthesis |
|
|
|
|
Aug 8, 2022
Provisional-Gov. Funding
United States
(None)
(None)
(None)
Utility-Gov. Funding
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
